Showing results (131-140 of 261) with videos related to

Sort By:
Pageof 27
Lancet (London, England)|August 13, 2019
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trialKristian Reich, April W Armstrong, Richard G Langley, et al.
Heart (British Cardiac Society)|August 21, 2021
Dilated cardiomyopathy: the role of genetics, highlighted in a family with Filamin C (FLNC) variantJason N Dungu, Samantha G Langley, Amy Hardy-Wallace, et al.
The British Journal of Dermatology|December 1, 2007
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)J-H Saurat, G Stingl, L Dubertret, et al.
The British Journal of Dermatology|November 25, 2017
Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumabR B Warren, A Brnabic, D Saure, et al.
Experimental Dermatology|June 5, 2023
Secukinumab versus guselkumab in the complete resolution of ustekinumab-resistant psoriatic plaques: The ARROW studyJames Krueger, Richard G Langley, Simon Nigen, et al.
The British Journal of Dermatology|October 18, 2018
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trialsR G Langley, A W Armstrong, M G Lebwohl, et al.
The British Journal of Dermatology|August 13, 2016
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasisK Reich, A Blauvelt, A Armstrong, et al.
Journal of Cutaneous Medicine and Surgery|May 4, 2005
Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004Lyn Guenther, Richard G Langley, Neil H Shear, et al.
Learning & Behavior|January 10, 2020
No evidence that footedness in pheasants influences cognitive performance in tasks assessing colour discrimination and spatial abilityMark A Whiteside, Mackenzie M Bess, Elisa Frasnelli, et al.
Dermatology and Therapy|November 4, 2023
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative ReviewAndrew Blauvelt, Richard G Langley, Kenneth B Gordon, et al.
Pageof 27